Critical insight at the speed of light.
Avalyra Biophotonics is a revolutionary MedTech company advancing a new standard of care. Our non-invasive, high-fidelity monitoring solutions are on path to enable frontline clinicians to detect fluid shifts, internal bleeding, and vascular instability earlier—supporting better decisions, fewer complications, and improved outcomes.
OUR MISSION is to close critical data gaps in both chronic and acute care – providing clinicians, care teams, and individuals with the clarity they need in real-time – transforming how essential critical care decisions are made and how chronic conditions are managed.
Avalyra Biophotonics is developing health technology platforms that combine advanced optical sensing, intelligent signal processing, edge computing, and cloud-enabled dashboards to track internal fluid dynamics and more – without the need for invasive line, blood draws, or bulky machines.
At the heart of Avalyra Biophotonics’ technology is a photonic-driven sensor system designed to detect subtle changes in vascular volume, plasma levels, and hematocrit in a non-invasive form factor.
We are building for speed, scale, and integration with hardware-agnostic platforms designed to evolve with clinical needs – from outpatient dialysis to battlefield trauma care.
MedTech Platforms Being Built for Critical Care Settings, Remote and Telehealth Applications, and Management of Chronic Conditions.
Our technology platforms are being designed to support multiple high-impact clinical applications:
Dialysis Optimization & Management
Preparing to usher in a new standard of care in dialysis management, with the goal of enabling personalized fluid management and reducing complications and hospitalizations over time..
Maternal Hemorrhage Detection
On path to address the second leading cause of maternal mortality worldwide, aiming to support real-time detection of internal hemorrhage across the care continuum, including postpartum.
Trauma & Defense
Building towards a goal of internal hemorrhage detection for battlefield triage, en route care, and remote deployments – empowering faster, smarter intervention when seconds matter.
Our Approach to Technology Development
Avalyra Biophotonics is building for scale and speed through a capital-efficient, streamlined approach. By leveraging strategic partnerships and a technology licensing model, our mission is to deliver life-saving innovations to market as rapidly as possible.
Avalyra Biophotonics is an IP company. Our Competitive Advantage and Strategic Driver of Innovation and growth are reflected in our strategic focus on IP Strategy.
Our current status reflects a de-risked, innovation-ready platform.
Device feasibility was confirmed through clinician-led testing with human participants in a controlled medical setting. These small-scale studies support our development pathway ahead of formal IRB-approved clinical trials scheduled for 2025.
IRB-approved clinical trials scheduled for Dialysis and Internal Hemorrhage (2025)
DoD SBIR-backed technology with a Phase III contract path
SAM.gov-registered and qualified Federal Contractor
Technology Readiness Level (TRL) 5, positioned for commercial development